ArticleKidney international reports2025
Pilot Study of Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin Shows Reduced Intrarenal Complement Activation in Patients With Diabetes and CKD.
Mia Jensen et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.